专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

111. 发明申请

US20170058029A1 HUMAN ANTIBODY-PRODUCING CELL 审中-公开
标题翻译：人体抗体生产细胞
公开(公告)号：US20170058029A1
公开(公告)日：2017-03-02
申请号：US15308085
申请日：2015-05-01
申请人： Chiome Bioscience Inc.
发明人： Shuichi Hashimoto , Tomoaki Uchiki , Shigeshisa Kawata , Kenjiro Asagoshi , Takashi Yabuki , Hitomi Sano , Shunsuke Miyai , Naoki Takahashi , Aki Takesue , Atsushi Sawada
IPC分类号： C07K16/28 , C07K16/24 , C12N5/0781 , C07K16/18
CPC分类号： C07K16/28 , C07K16/18 , C07K16/22 , C07K16/244 , C07K2317/14 , C07K2317/21 , C07K2317/51 , C07K2317/515 , C07K2317/565 , C12N5/00 , C12N5/0635 , C12N5/10 , C12N15/00 , C12N15/09 , C12N2510/02 , C40B40/02
摘要： It is an object of the present invention to provide a chicken B cell that expresses a variety of human antibodies. The solution to the problem in the present invention is a chicken B cell, in which, in an antibody light chain gene locus thereof, all or a part of a DNA sequence derived from a human antibody light chain variable region and a human antibody light chain constant region are inserted, or the antibody light chain gene locus is replaced with all or a part of a DNA sequence derived from a human antibody light chain variable region and a human antibody light chain constant region, and in an antibody heavy chain gene locus thereof, all or a part of a DNA sequence derived from a human antibody heavy chain variable region and a human antibody heavy chain constant region are inserted, or the antibody heavy chain gene locus is replaced with all or a part of a DNA sequence derived from a human antibody heavy chain variable region and a human antibody heavy chain constant region, and in an antibody light chain pseudogene locus thereof, two or more DNA sequences derived from human antibody light chain variable regions are inserted, or the antibody light chain pseudogene locus is replaced with two or more DNA sequences derived from human antibody light chain variable regions, and/or in an antibody heavy chain pseudogene locus thereof, two or more DNA sequences derived from human antibody heavy chain variable regions are inserted, or the antibody heavy chain pseudogene locus is replaced with two or more DNA sequences derived from human antibody heavy chain variable regions.
摘要翻译：本发明的目的是提供一种表达多种人抗体的鸡B细胞。本发明的问题的解决方案是一种鸡B细胞，其中在抗体轻链基因座中，全部或部分源自人抗体轻链可变区和人抗体轻链的DNA序列或者抗体轻链基因座被全部或一部分来源于人抗体轻链可变区和人抗体轻链恒定区的DNA序列替换，并且在其抗体重链基因座中插入来自人抗体重链可变区和人抗体重链恒定区的DNA序列的全部或一部分，或者将全部或部分来源于人抗体重链可变区和人抗体重链恒定区，并且在抗体轻链假基因座中，衍生自人抗体轻链的两个或多个DNA序列插入可变区，或者将抗体轻链假基因座用来自人抗体轻链可变区和/或其抗体重链假基因座的两个或更多个DNA序列替换，来自人的两个或更多个DNA序列插入抗体重链可变区，或者用来自人抗体重链可变区的两个或多个DNA序列替换抗体重链假基因座。

112. 发明申请

US20170049884A1 USE OF ANTI-CCR5 ANTIBODIES IN GRAFT VERSUS HOST DISEASE 审中-公开
标题翻译：在抗病毒性疾病中使用抗CCR5抗体
公开(公告)号：US20170049884A1
公开(公告)日：2017-02-23
申请号：US15119103
申请日：2015-02-18
申请人： CytoDyn Inc.
发明人： Bruce Alan Montgomery
IPC分类号： A61K39/395 , A61K45/06 , A61K9/00 , A61K31/496 , A61K31/351 , A61K31/55 , A61K31/46 , C07K16/28 , A61K31/506
CPC分类号： A61K39/3955 , A61K9/0019 , A61K9/0053 , A61K31/351 , A61K31/46 , A61K31/496 , A61K31/506 , A61K31/55 , A61K39/39541 , A61K45/06 , C07K16/2866 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C07K2317/76 , C07K2317/92 , A61K2300/00
摘要： This composition and method provides for a method for reducing GVHD in a human subject which comprises administering to the subject at a predefined interval effective GVHD-reducing doses of (a) a humanized antibody designated PRO 140, or of (b) an anti-CCR5 receptor monoclonal antibody. This invention also provides a method for inhibiting in a human subject the onset or progression of GVHD. This invention also provides a method for treating a subject with GVHD comprising administering to the subject (a) a monoclonal antibody which (i) binds to a CCR5 receptor on the surface of the subject's CD4.sup.+ cells, and (b) a non-antibody CCR5 receptor antagonist, in amounts effective to treat the subject.
摘要翻译：该组合物和方法提供了用于减少人受试者中的GVHD的方法，其包括以预定间隔向受试者施用有效的GVHD减少剂量的（a）命名为PRO 140的人源化抗体或（b）抗CCR5 受体单克隆抗体。本发明还提供了抑制人受试者GVHD发病或进展的方法。本发明还提供用于治疗患有GVHD的受试者的方法，其包括向受试者施用（a）单克隆抗体，所述单克隆抗体（i）结合受试者的CD4 +细胞的表面上的CCR5受体，和（b）非抗体CCR5受体拮抗剂，其量有效治疗受试者。

113. 发明申请

US20170044224A1 A PROTEIN SECRETORY FACTOR WITH HIGH SECRETORY EFFICIENCY AND AN EXPRESSION VECTOR COMPRISING THE SAME 审中-公开
标题翻译：具有高密度效率的蛋白质秘密因子和包含该蛋白质的表达载体
公开(公告)号：US20170044224A1
公开(公告)日：2017-02-16
申请号：US15307322
申请日：2015-04-30
申请人： LG LIFE SCIENCES LTD.
发明人： Seung Hae KIM , Yeon Chul KIM , Saem JUNG
IPC分类号： C07K14/47 , C12P21/02 , C07K16/00
CPC分类号： C07K14/47 , C07K14/82 , C07K16/00 , C07K2317/51 , C07K2317/515 , C07K2319/00 , C07K2319/02 , C12N15/85 , C12P21/02
摘要： The present invention relates to a novel protein secretion factor, a vector including a nucleic acid sequence encoding the protein secretion factor, and a transformed cell into which the vector is introduced. The invention also relates to a method of producing a target protein using the transformed cell including the vector.
摘要翻译：本发明涉及一种新型蛋白质分泌因子，包含编码蛋白质分泌因子的核酸序列的载体和引入载体的转化细胞。本发明还涉及使用包含载体的转化细胞产生靶蛋白的方法。

114. 发明申请

US20170015741A1 TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS BY AN INHIBITOR OF COMPLEMENT 有权
标题翻译：通过补充抑制剂治疗寄生虫病人血液白血病患者
公开(公告)号：US20170015741A1
公开(公告)日：2017-01-19
申请号：US15284015
申请日：2016-10-03
申请人： Alexion Pharmaceuticals, Inc.
发明人： Leonard BELL , Russell P. ROTHER
IPC分类号： C07K16/18
CPC分类号： C07K16/18 , A61K9/0019 , A61K31/7105 , A61K38/00 , A61K2039/505 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C07K2317/565
摘要： Eculizumab, a humanized monoclonal antibody against C5 that inhibits terminal complement activation, showed activity in a preliminary 12-week open-label trial in a small cohort of patients with paroxysmal nocturnal hemoglobinuria (PNH). The present study examined whether chronic eculizumab therapy could reduce intravascular hemolysis, stabilize hemoglobin levels, reduce transfusion requirements, and improve quality of life in a double-blind, randomized, placebo-controlled, multi-center global Phase III trial. It has been found that eculizumab stabilized hemoglobin levels, decreased the need for transfusions, and improved quality of life in PNH patients via reduced intravascular hemolysis. Chronic eculizumab treatment appears to be a safe and effective therapy for PNH.
摘要翻译：厄洛珠单抗是抑制末端补体激活的C5的人源化单克隆抗体，在阵发性夜间血红蛋白尿（PNH）患者的小队列中，在初步的12周开放标签试验中显示出活性。本研究检查了在双盲，随机，安慰剂对照，多中心全球III期试验中，慢性eculizumab治疗是否可以减少血管内溶血，稳定血红蛋白水平，降低输血需求，提高生活质量。已经发现，通过减少血管内溶血，厄库珠单抗稳定了血红蛋白水平，降低了输血的需要，并改善PNH患者的生活质量。慢性eculizumab治疗似乎是PNH的安全有效的治疗方法。

115. 发明申请

US20170002082A1 ACTIVATABLE ANTIBODIES THAT BIND INTERLEUKIN-6 RECEPTOR AND METHODS OF USE THEREOF 审中-公开
标题翻译：结合白细胞介素-6受体的活性抗体及其使用方法
公开(公告)号：US20170002082A1
公开(公告)日：2017-01-05
申请号：US15271897
申请日：2016-09-21
申请人： CytomX Therapeutics, Inc.
发明人： James William West , Jason Gary Sagert , Daniel Robert Hostetter , Stephen James Moore , Margaret Thy Luu Nguyen , Olga Vasiljeva , Jeanne Grace Flandez
IPC分类号： C07K16/28
CPC分类号： C07K16/2866 , A61K47/65 , A61K2039/505 , C07K2317/51 , C07K2317/515 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/90 , C07K2317/92 , C07K2317/94 , C07K2319/50
摘要： The invention relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to interleukin-6 receptor (IL-6R), and to methods of making and using these anti-IL-6R activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
摘要翻译：本发明一般涉及可激活的抗体，其包括特异性结合白细胞介素-6受体（IL-6R）的掩蔽部分（MM），可切割部分（CM）和抗体（AB），以及制备和使用这些抗IL-6R可激活的抗体在各种治疗，诊断和预防指征中。

116. 发明申请

US20160376357A1 ANTI-C5A ANTIBODIES 有权
标题翻译：抗C5A抗体
公开(公告)号：US20160376357A1
公开(公告)日：2016-12-29
申请号：US15262697
申请日：2016-09-12
申请人： Alexion Pharmaceuticals, Inc.
发明人： Russell P. ROTHER , Douglas L. SHERIDAN , Paul P. TAMBURINI , Yuchun ZHANG
IPC分类号： C07K16/18 , A61K45/06 , A61K47/48 , A61K39/395
CPC分类号： C07K16/18 , A61K39/3955 , A61K45/06 , A61K47/60 , A61K2039/505 , C07K16/28 , C07K16/461 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/41 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/71 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease.
摘要翻译：本公开尤其涉及结合C5a的抗体或其抗原结合片段以及在用于治疗或预防补体相关病症例如但不限于非典型溶血性尿毒症综合征的方法中使用抗体，年龄相关性黄斑变性，类风湿性关节炎，败血症，严重烧伤，抗磷脂脂质综合征，哮喘，狼疮肾炎，古德帕斯彻综合征和慢性阻塞性肺疾病。

117. 发明申请

US20160368991A1 SOLUBLE MIC NEUTRALIZING MONOCLONAL ANTIBODY FOR TREATING CANCER 有权
标题翻译：可溶性MIC中和用于治疗癌症的单克隆抗体
公开(公告)号：US20160368991A1
公开(公告)日：2016-12-22
申请号：US14900510
申请日：2014-07-03
申请人： UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
发明人： Jennifer WU
IPC分类号： C07K16/28 , C07K16/30
CPC分类号： C07K16/2833 , A01K67/0278 , A01K2217/072 , A01K2227/105 , A01K2267/0331 , A61K2039/505 , C07K16/2851 , C07K16/30 , C07K2317/24 , C07K2317/31 , C07K2317/51 , C07K2317/515 , C07K2317/54 , C07K2317/55 , C07K2317/565 , C07K2317/569 , C07K2317/622 , C07K2317/624 , C07K2317/626 , C07K2317/73 , C07K2317/76
摘要： Disclosed are compositions and methods relating to antibodies that bind soluble Major Histocompatibility Complex class I chain-related (sMIC). Specifically, disclosed are antibodies designed or selected to inhibit sMIC (e.g. to neutralize sMIC) shed from MIC+ tumors. Further disclosed are methods of using the antibodies for the treatment of MlC-positive cancers.
摘要翻译：公开了与可溶性主要组织相容性复合物I类链相关（sMIC）结合的抗体相关的组合物和方法。具体地，公开了设计或选择以抑制从MIC +肿瘤脱落的sMIC（例如中和sMIC）的抗体。进一步公开的是使用抗体治疗MlC阳性癌症的方法。

118. 发明申请

US20160368988A1 HUMAN CD3 BINDING ANTIBODY 有权
标题翻译：人CD3结合抗体
公开(公告)号：US20160368988A1
公开(公告)日：2016-12-22
申请号：US15205629
申请日：2016-07-08
申请人： Merus N.V.
发明人： Alexander Berthold Hendrik BAKKER , Pieter Fokko VAN LOO
IPC分类号： C07K16/28
CPC分类号： C07K16/2809 , A61K39/39591 , C07K16/2851 , C07K2317/21 , C07K2317/31 , C07K2317/51 , C07K2317/515 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/55 , C07K2317/56 , C07K2317/71 , C07K2317/73 , C07K2317/92 , C07K2317/94
摘要： The invention is among others concerned with human CD3 binding antibodies comprising a heavy chain and light chain wherein said heavy chain comprises a variable region that comprises the amino acid sequence: QVQLV QSGGG VVQPG RSLRL SCVAS GFTFS SYGMH WVRQA PGKGL EWVAA IWYX1X2RKQDY ADSVK GRFTI SRDNS KNTLY LQMNS LRAED TAVYY CTRGT GYNWF DPWGQ GTLVT VSS with 0-5 amino acid insertions, deletions, substitutions, additions or a combination thereof at one or more positions other than the position indicated by X1X2; wherein X1=N and X2=A; X1=N and X2=T; X1=S and X2=G; X1=H and X2=G; X1=D and X2=G; or X1=H and X2=A. The invention is also concerned with bispecific antibodies that have a heavy chain as defined herein above. The invention is also concerned with methods of production of the antibody, cells producing the antibody and with (medical) uses of the antibody.
摘要翻译：本发明涉及包含重链和轻链的人CD3结合抗体，其中所述重链包含包含氨基酸序列的可变区：QVQLV QSGGG VVQPG RSLRL SCVAS GFTFS SYGMH WVRQA PGKGL EWVAA IWYX1X2RKQDY ADSVK GRFTI SRDNS KNTLY LQMNS LRAED TAVYY CTRGT GYNWF DPWGQ GTLVT VSS，其除了X1X2所示位置以外的一个或多个位置具有0-5个氨基酸插入，缺失，替换，添加或组合; 其中X1 = N和X2 = A; X1 = N，X2 = T; X1 = S，X2 = G; X1 = H，X2 = G; X1 = D，X2 = G; 或X1 = H，X2 = A。本发明还涉及具有如上文所定义的重链的双特异性抗体。本发明还涉及产生抗体的方法，产生抗体的细胞和抗体的（医学）用途。

119. 发明申请

US20160368984A1 Compositions Comprising Antibodies to Lingo or Fragments Thereof 有权
标题翻译：包含针对Lingo或其片段的抗体的组合物
公开(公告)号：US20160368984A1
公开(公告)日：2016-12-22
申请号：US15165279
申请日：2016-05-26
申请人： Biogen MA Inc.
发明人： Sha Mi , R. Blake Pepinsky , Christilyn Graff
IPC分类号： C07K16/28 , A61K45/06 , A61K47/48 , A61K39/395
CPC分类号： C07K16/2803 , A61K39/3955 , A61K45/06 , A61K47/60 , A61K47/6849 , A61K47/6879 , A61K2039/505 , C07K16/18 , C07K16/28 , C07K2317/21 , C07K2317/35 , C07K2317/41 , C07K2317/51 , C07K2317/515 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/71 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/01
摘要： Endogenous LINGO-1 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous LINGO-1 function, such anti-LINGO-1 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for LINGO-1, and methods of using such antibodies as antagonists of endogenous LINGO-1 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-LINGO-1 antibody
摘要翻译：内源性LINGO-1是神经元存活，轴突再生，少突胶质细胞分化和髓鞘形成的负调节因子。阻断内源性LINGO-1功能的分子，如抗LINGO-1抗体可用作治疗神经元和少突胶质细胞功能障碍的治疗剂。本发明提供对LINGO-1特异性的抗体，以及使用这些抗体作为内源性LINGO-1功能的拮抗剂的方法。本发明还提供特异性杂交瘤和源自噬菌体文库的单克隆抗体，编码这些抗体的核酸，以及包含这些抗体的载体和宿主细胞。本发明还提供了在脊椎动物中促进少突胶质细胞存活和髓鞘形成的方法，包括对需要这种治疗的脊椎动物施用有效量的抗LINGO-1抗体

120. 发明申请

US20160362476A1 METHODS AND COMPOSITIONS FOR PRODUCING A CHIMERIC POLYPEPTIDE 有权
标题翻译：用于生产半固化多肽的方法和组合物
公开(公告)号：US20160362476A1
公开(公告)日：2016-12-15
申请号：US15175739
申请日：2016-06-07
申请人： AxioMx, Inc.
发明人： Michael WEINER , Margaret KISS , Melissa BATONICK
IPC分类号： C07K16/00
CPC分类号： C07K16/00 , C07K2317/35 , C07K2317/51 , C07K2317/515 , C07K2317/622 , C07K2319/00 , C12N15/1037 , C12N15/63
摘要： The present invention provides methods and compositions for converting a first polypeptide into a chimeric polypeptide. The invention includes two vectors: a first vector including the sequence of the first polypeptide and a second vector including a second polypeptide. The vectors include complementary site-specific recombination motifs such that site-specific recombination between the two vectors results in the generation of a chimeric polypeptide including at least a portion of the first polypeptide and at least a portion of the second polypeptide. A site-specific recombination motif may be positioned within an intron or within a coding sequence on the first or second vector.
摘要翻译：本发明提供了将第一多肽转化为嵌合多肽的方法和组合物。本发明包括两个载体：包含第一多肽的序列的第一载体和包含第二多肽的第二载体。载体包括互补位点特异性重组基序，使得两个载体之间的位点特异性重组导致产生嵌合多肽，其包括第一多肽的至少一部分和第二多肽的至少一部分。位点特异性重组基序可以位于第一或第二载体的内含子内或编码序列内。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式